-

Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC, a global vertically integrated biopharmaceutical company, announced the appointment of Mandar Borkar as Global Chief Financial Officer (CFO) and Ross Oehler as Global Chief Legal Officer (CLO).

“We are pleased to welcome Mandar Borkar and Ross Oehler to the management team,” said Chirag and Chintu Patel, Co-Founders of Kashiv BioSciences, “With two approved products on the market and a rapidly advancing pipeline, we are confident their expertise will play a pivotal role in advancing Kashiv to new heights.”

Mandar Borkar brings over 25 years of experience in the pharmaceutical industry managing complex financial structures, leading M&A and finance transformation, and governing global finance teams. Mr. Borkar’s career includes roles at Mahindra & Mahindra, Parke Davis, Lupin, and Watson Pharma. As CFO of Indoco Remedies, he optimized operational efficiency and positioned the company for long-term financial growth. Most recently, Mr. Borkar led Abbott’s Financial Controlling Function, ensured Financial Reporting and Compliance, and drove advancements in finance operations. He is a member of the Institute of Chartered Accountants of India and Institute of Cost and Management Accountants of India. Mr. Borkar holds a B Com from Mumbai University.

Ross Oehler brings over 30 years of biopharmaceutical experience from Sanofi-Aventis, Cephalon Inc., and Johnson Matthey, Inc., handling complex legal matters. Mr. Oehler heads the global Legal and IP groups, providing support on matters including IP, litigation, corporate governance, regulatory policy, compliance, and commercial transactions. Mr. Oehler has been involved in numerous IP and commercial disputes in the US Federal Courts, International Trade Commission, and post-grant review proceedings in US and European Patent Offices. He is a member of the Association of Corporate Counsel, Association of Corporate Patent Counsel, and served on the Board of Directors of the IP Owners Association. Mr. Oehler holds a JD from New York Law School and Bachelor’s degree in Biology from Gettysburg College.

About Kashiv:

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets. Kashiv BioSciences, LLC in the United States, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines.

Kashiv BioSciences, LLC


Release Versions

More News From Kashiv BioSciences, LLC

Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv BioSciences” or the “Company”), a fully integrated biopharmaceutical company, today announced that it has entered into a senior secured credit agreement with GoldenTree Asset Management (“GoldenTree”) as the sole lender. The $150 million credit facility supports Kashiv BioSciences in advancing its world-class infrastructure, enabling the Company to pursue its research, development, and manufacturing strategy in both the U.S. an...

UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application (MAA) for ADL-018, the Company’s proposed biosimilar for Xolair® (omalizumab). The acceptance marks a critical milestone in our commitment to developing cost-effective therapies to patients with moderate to severe persistent asthma, chronic rhinosinusitis wi...

Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial launch in this market. This marks an important step in Kashiv’s strategy to expand access to high-quality biosimilars in global markets. PexegraTM is a long-acting G-CSF biosimilar indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients wit...
Back to Newsroom